Format

Send to

Choose Destination
See comment in PubMed Commons below
Trends Mol Med. 2014 May;20(5):242-50. doi: 10.1016/j.molmed.2013.12.003. Epub 2014 Jan 20.

Addicted to secrete - novel concepts and targets in cancer therapy.

Author information

1
Inserm U1053, F-33000 Bordeaux, France; University Bordeaux-Segalen, F-33000 Bordeaux, France. Electronic address: nicolas.dejeans@gmail.com.
2
University of Lyon, 69000 Lyon, France; UMR CNRS 5286, INSERM 1052, Cancer Research Center of Lyon, 69000 Lyon, France.
3
Biomedical Neuroscience Institute, ICBM, Faculty of Medicine, University of Chile, Santiago, Chile; Neurounion Biomedical Foundation, Santiago, Chile; Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA, USA.
4
Laboratory Regulation of Membrane Traffic, Institute of Molecular and Cell Biology, Singapore, Singapore; Department of Biochemistry, National University of Singapore, Singapore, Singapore.
5
Cell Signaling Unit, p53 Signal Transduction Laboratories, Edinburgh Cancer Research Centre, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XR, UK.
6
Department of Cellular and Molecular Medicine, University of Leuven (KU Leuven), Leuven, Belgium.
7
Apoptosis Research Centre, School of Natural Sciences, NUI Galway, Galway, Ireland.
8
Inserm U1053, F-33000 Bordeaux, France; University Bordeaux-Segalen, F-33000 Bordeaux, France; University of Lyon, 69000 Lyon, France. Electronic address: eric.chevet@inserm.fr.

Abstract

The unfolded protein response (UPR) mediates the adaptation of the secretory pathway (SP) to fluctuations in cellular protein demand or to environmental variations. Recently, drug screenings have confirmed the therapeutic potential of targeting the UPR in cancer models. However, the UPR may not be the only druggable target of the SP. Moreover, recent studies have revealed other contributions of the SP to cancer development. This article does not intend to describe the well-established implication of UPR signaling pathways in cancer cell life and cell decision, but rather aims at defining the concept of 'tumor cell secretory addiction', from molecular, cellular, and therapeutic perspectives. Furthermore, the implication of UPR modulations in this context will be discussed.

KEYWORDS:

cancer therapy; secretory pathway; unfolded protein response

PMID:
24456621
DOI:
10.1016/j.molmed.2013.12.003
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center